PFE - Pfizer Inc.
| Previous close | 38.54 |
| Open | 38.52 |
| Bid | 38.31 x 3000 |
| Ask | 38.32 x 4000 |
| Day's range | 38.07 - 38.68 |
| 52-week range | 33.97 - 44.56 |
| Volume | 14,862,155 |
| Avg. volume | 18,571,131 |
| Market cap | 212B |
| Beta (5Y Monthly) | 0.65 |
| PE ratio (TTM) | 13.56 |
| EPS (TTM) | 2.83 |
| Earnings date | 27 Jan 2020 - 31 Jan 2020 |
| Forward dividend & yield | 1.44 (3.74%) |
| Ex-dividend date | 2019-11-07 |
| 1y target est | 41.45 |
- Zacks
Jabil (JBL) to Report Q1 Earnings: What's in the Cards?
Jabil's (JBL) first-quarter fiscal 2020 results are expected to benefit from contract wins in healthcare, automotive, cloud and 5G end-markets.
- Zacks
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up
Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.
- Business Wire
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
- Zacks
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
- Business Wire
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers.
- Zacks
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
- Zacks
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
- Zacks
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
- Zacks
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
- Yahoo Finance
The biggest deals and attempted deals of the 2010s
As 2019 ends with major deals, Yahoo Finance looks back at the decade on the mergers and acquisitions in Corprorate America.
- Zacks
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
- Zacks
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
- Zacks
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US
Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.
- Zacks
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.
- Zacks
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
- Zacks
AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC
AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.
- Zacks
Why Is Pfizer (PFE) Up 0.4% Since Last Earnings Report?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Here's Why Merck's (MRK) Shares Are Up This Year
Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.
- Zacks
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer
Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
- Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, and Michael Vincent, Senior Vice President and Chief Scientific Officer, Inflammation and Immunology, at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 10:15 a.m. Eastern Standard Time. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.
- Reuters
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
The full scope of Novartis' $500 million plan, revealed to Reuters in an interview with the company's gene therapy chief, has not been previously disclosed. It is second only to Pfizer, which has allocated $600 million to build its own gene therapy manufacturing plants, according to filings and interviews with industry executives.
- Zacks
The Zacks Analyst Blog Highlights: Pfizer, Netflix, Dominion, Costco and Charles Schwab
The Zacks Analyst Blog Highlights: Pfizer, Netflix, Dominion, Costco and Charles Schwab
- Zacks
Top Research Reports for Pfizer, Netflix & Dominion Energy
Top Research Reports for Pfizer, Netflix & Dominion Energy
